NCT06461351View on ClinicalTrials.gov

Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

May 30, 2039

Study Completion Date

March 30, 2040

Conditions
B-cell Tumors
Interventions
OTHER

Inaticabtagene autoleucel Injection

Inaticabtagene autoleucel Injection

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Juventas Cell Therapy Ltd.

INDUSTRY